Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
Status:
Completed
Trial end date:
2019-07-22
Target enrollment:
Participant gender:
Summary
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on
Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.